ArticleGalen medical journal2025
Preoperative Intravenous Desmopressin and Perioperative Blood Loss in Patients Undergoing Major Spine Surgery : Preoperative Intravenous Desmopressin and Perioperative Blood Loss in Spine Surgery Patients.
Article in Galen medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Major spine surgeries often involve significant blood loss, increasing transfusion risks and postoperative complications. Desmopressin, a synthetic vasopressin analog, may reduce bleeding by enhancing clotting factor release, but its efficacy in spine surgery remains understudied. This study evaluated the efficacy of preoperative intravenous desmopressin in reducing perioperative blood loss and transfusion requirements in patients undergoing major spine surgery. Materials and Methods: A double-blind, randomized, placebo-controlled trial was conducted at Shahid Rajaei Hospital, Iran. Fifty-five patients undergoing major spinal surgery were randomized to receive either 0.3 μg/kg desmopressin (n=25) or placebo (n=30) during anesthesia induction. Primary outcomes included intraoperative blood loss (measured hourly) and transfusion volume. Secondary outcomes included postoperative sodium levels, creatinine, urine output, and hospital stay. Statistical analyses used Student's t-test, Chi-square, and repeated measures ANOVA. Results: Desmopressin significantly reduced intraoperative blood loss during the first hour (336.00± 125.43 vs. 398.33±85.58 mL, P=0.034) and second hour (530.95±188.07 vs. 756.67 ± 242.65 mL, P=0.003) compared to placebo. Total transfusion volume was lower in the desmopressin group (724.79 ± 429.06 vs. 1396.55±325.94 mL, P=0.001), with fewer intraoperative packed red blood cell transfusions (16% vs. 40%, P = 0.050). Postoperative creatinine levels were lower with desmopressin (1.16 ± 0.30 vs. 1.40 ± 0.32 mg/dL, P=0.009), but sodium levels and urine output were comparable. Hemodynamic stability and hospital stay did not differ significantly. Conclusion: Preoperative desmopressin reduced early intraoperative blood loss and transfusion requirements in major spine surgery without significant adverse effects. These findings support its use as a hemostatic adjunct, though further studies are needed to confirm long-term safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.